Iuliia Makarenko1, Alyona Mazhnaya2, Maxim Polonsky3, Ruthanne Marcus3, Martha J Bojko3, Sergii Filippovych2, Sandra Springer3, Sergii Dvoriak4, Frederick L Altice5. 1. ICF Alliance for Public Health, Kyiv, Ukraine. Electronic address: Makarenko@aph.org.ua. 2. ICF Alliance for Public Health, Kyiv, Ukraine. 3. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA. 4. Ukrainian Institute on Public Health Policy, Kyiv, Ukraine. 5. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, New Haven, CT, USA.
Abstract
BACKGROUND: Coverage with opioid agonist treatments (OAT) that include methadone and buprenorphine is low (N=8400, 2.7%) for the 310,000 people who inject drugs (PWID) in Ukraine. In the context of widespread negative attitudes toward OAT in the region, patient-level interventions targeting the barriers and willingness to initiate OAT are urgently needed. METHODS: A sample of 1179 PWID with opioid use disorder not currently on OAT from five regions in Ukraine was assessed using multivariable logistic regression for independent factors related to willingness to initiate OAT, stratified by their past OAT experience. RESULTS: Overall, 421 (36%) PWID were willing to initiate OAT. Significant adjusted odds ratios (aOR) for covariates associated with the willingness to initiate OAT common for both groups included: higher injection frequency (previously on OAT: aOR=2.7; never on OAT: aOR=1.8), social and family support (previously on OAT: aOR=2.0; never on OAT: aOR=2.0), and positive attitude towards OAT (previously on OAT: aOR=1.3; never on OAT: aOR=1.4). Among participants previously on OAT, significant correlates also included: HIV-negative status (aOR=2.6) and depression (aOR=2.7). Among participants never on OAT, however, living in Kyiv (aOR=4.8) or Lviv (aOR=2.7), previous imprisonment (aOR=1.5), registration at a Narcology service (aOR=1.5) and recent overdose (aOR=2.6) were significantly correlated with willingness to initiate OAT. CONCLUSIONS: These findings emphasize the need for developing interventions aimed to eliminate existing negative preconceptions regarding OAT among PWID with opioid use disorder in Ukraine, which should be tailored to meet the needs of specific characteristics of PWID in geographically distinct setting based upon injection frequency, prior incarceration, and psychiatric and HIV status.
BACKGROUND: Coverage with opioid agonist treatments (OAT) that include methadone and buprenorphine is low (N=8400, 2.7%) for the 310,000 people who inject drugs (PWID) in Ukraine. In the context of widespread negative attitudes toward OAT in the region, patient-level interventions targeting the barriers and willingness to initiate OAT are urgently needed. METHODS: A sample of 1179 PWID with opioid use disorder not currently on OAT from five regions in Ukraine was assessed using multivariable logistic regression for independent factors related to willingness to initiate OAT, stratified by their past OAT experience. RESULTS: Overall, 421 (36%) PWID were willing to initiate OAT. Significant adjusted odds ratios (aOR) for covariates associated with the willingness to initiate OAT common for both groups included: higher injection frequency (previously on OAT: aOR=2.7; never on OAT: aOR=1.8), social and family support (previously on OAT: aOR=2.0; never on OAT: aOR=2.0), and positive attitude towards OAT (previously on OAT: aOR=1.3; never on OAT: aOR=1.4). Among participants previously on OAT, significant correlates also included: HIV-negative status (aOR=2.6) and depression (aOR=2.7). Among participants never on OAT, however, living in Kyiv (aOR=4.8) or Lviv (aOR=2.7), previous imprisonment (aOR=1.5), registration at a Narcology service (aOR=1.5) and recent overdose (aOR=2.6) were significantly correlated with willingness to initiate OAT. CONCLUSIONS: These findings emphasize the need for developing interventions aimed to eliminate existing negative preconceptions regarding OAT among PWID with opioid use disorder in Ukraine, which should be tailored to meet the needs of specific characteristics of PWID in geographically distinct setting based upon injection frequency, prior incarceration, and psychiatric and HIV status.
Authors: Steffanie A Strathdee; Erin P Ricketts; Steven Huettner; Lee Cornelius; David Bishai; Jennifer R Havens; Peter Beilenson; Charles Rapp; Jacqueline J Lloyd; Carl A Latkin Journal: Drug Alcohol Depend Date: 2005-12-20 Impact factor: 4.492
Authors: Sandra A Springer; Sarah Larney; Zahra Alam-Mehrjerdi; Frederick L Altice; David Metzger; Steven Shoptaw Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali Journal: J Gen Intern Med Date: 2005-12-07 Impact factor: 5.128
Authors: R S Broadhead; D D Heckathorn; D L Weakliem; D L Anthony; H Madray; R J Mills; J Hughes Journal: Public Health Rep Date: 1998-06 Impact factor: 2.792
Authors: Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; James A Peterson; Heather S Reisinger; Shannon G Mitchell; Monique E Wilson; Michael H Agar; Barry S Brown Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: Celeste M Caviness; Christina Hatgis; Bradley J Anderson; Cynthia Rosengard; Susan M Kiene; Peter D Friedmann; Michael D Stein Journal: J Stud Alcohol Drugs Date: 2009-01 Impact factor: 2.582
Authors: Olena Iakunchykova; Anna Meteliuk; Alexei Zelenev; Alyona Mazhnaya; Melissa Tracy; Frederick L Altice Journal: Int J Drug Policy Date: 2018-04-12
Authors: Julia Rozanova; Olga Morozova; Lyuba Azbel; Chethan Bachireddy; Jacob M Izenberg; Tetiana Kiriazova; Sergiy Dvoryak; Frederick L Altice Journal: J Urban Health Date: 2018-08 Impact factor: 3.671